看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' s2 ~7 R0 y3 u) y2 Y, ~( i
. A: L1 l, ~" @" [. W% k
& w3 J7 R) ~+ Q( ^( ]3 F+ YCurrently available feasibility data for possible combination strategies. + h; L7 k% I) F. K6 ]& m7 V
————————————————————————————————
3 P- y& y3 v+ k. Z* G) sCombination Feasibility according to preliminary data
@0 o7 h% N8 t7 |3 M$ }——————————————————————————————————6 e1 H' u) t5 G" r% k. n4 t6 l
Bevacizumab + sorafenib Yes, reduced dose
' @, ]% q; p/ J! w: i& d2 lBevacizumab + sunitinib† No
8 ]" [9 N2 m! P. c" P1 }1 UBevacizumab + temsirolimus Yes
# w/ q* g+ d4 ?# IBevacizumab + everolimus Yes " h; z- o5 b' G! a) h* q
Sorafenib + sunitinib ? 2 S' {7 E' O5 l) y" I3 E% p
Sorafenib + temsirolimus Yes, reduced dose
: r. R! ]+ w# t; B8 o8 w$ OSorafenib + everolimus Yes, reduced dose
6 b. e, P+ k# v4 nSunitinib + temsirolimus† No . T7 s0 y0 R0 e% f8 V& T
Sunitinib + everolimus ? # q3 ?- e. M H0 k4 T
Temsirolimus + everolimus ?
; R! z9 L$ w& A* z, a# A9 p- E9 t————————————————————
$ ?7 Y. G' U# G9 @8 I- n†Led to US FDA warning.; c1 J7 E! L6 p
?: As yet unattempted combination.
6 ?8 S6 A1 A9 l2 d |
显身卡
/ Z# Y5 m" b; t- J+ ^! c/ y7 {9 `
